BSX stock forecast, quote, news & analysis
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts... Show more
Why Boston Scientific (BSX) Stock Is Down -11.9% in the Last 30 Days
Key Takeaways
- Boston Scientific shares fell roughly 11.9% over the last 30 days, from a closing price of $48.37 to $42.60.
- The decline was driven primarily by the company's disclosure that an August cybersecurity incident would likely cause it to miss third-quarter and full-year 2026 guidance.
- Longer-running headwinds in the FARAPULSE electrophysiology and WATCHMAN franchises have compounded investor concerns about growth.
- Over the last quarter, the stock slid about 5–6%, having first rallied to a mid-August high near $52 before reversing lower.
- Investors are focused on the company's third-quarter results, scheduled for late October, for updated financial guidance.
Boston Scientific (BSX) Company Overview and Market Position
Boston Scientific Corporation is a global medical technology company headquartered in Marlborough, Massachusetts, that develops, manufactures, and markets devices used across interventional medical specialties. The company's portfolio is organized into two primary segments: Cardiovascular, which includes interventional cardiology, cardiac rhythm management, electrophysiology, and peripheral interventions, and MedSurg, which encompasses endoscopy, urology, and neuromodulation.
Two franchises have long anchored investor interest in the stock. FARAPULSE, the company's pulsed field ablation (PFA) system, is a leading treatment for atrial fibrillation, while WATCHMAN is a left atrial appendage closure device used to reduce stroke risk. Boston Scientific's scale, broad product pipeline, and historically strong margin profile have made it one of the most closely followed names in medtech.
Boston Scientific (BSX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Boston Scientific shares declined from a closing price of $48.37 on September 2, 2026, to $42.60 on October 2, 2026, a drop of approximately 11.9%. The selling was concentrated around a September 8 disclosure, when the stock fell sharply after the company warned it would likely miss its financial guidance.
The last quarter tells a similar but broader story. Shares traded near $45 in early July, then rallied to a high of roughly $52 by mid-August before reversing. From the early-July level to early October, the stock declined about 5–6%, reflecting a peak-to-trough retreat of more than 15% from the August high. The overall quarterly trend has been decidedly negative as growth concerns mounted.
What Drove BSX Stock Price in the Last 30 Days
The single largest catalyst over the past 30 days was Boston Scientific's September 8 regulatory filing, in which the company said a cybersecurity incident disclosed in late August had disrupted manufacturing and order shipments globally. Management stated it was unlikely to meet its previously issued third-quarter and full-year 2026 net sales and adjusted earnings per share guidance, sending the stock down about 4% to 5% in premarket and early trading.
Beyond the cyberattack, investors continued to weigh competitive pressure in electrophysiology. FARAPULSE faces growing competition from rivals such as Medtronic (MDT), Johnson & Johnson (JNJ), and Abbott (ABT), which have been gaining share in the pulsed field ablation market. Slower WATCHMAN referrals tied to recent stroke-risk clinical data have further pressured the growth narrative that historically supported the stock's premium valuation.
What Drove BSX Stock Performance Over the Last Quarter
The quarterly decline reflects a multi-month repricing of Boston Scientific's growth outlook. Management has acknowledged greater-than-expected U.S. electrophysiology share erosion and a moderation in WATCHMAN demand, leading to successive reductions in full-year 2026 guidance. The company has also announced a restructuring program targeting approximately $500 million in annual run-rate savings by the end of 2029.
The late-August cyberattack added an operational disruption to what were already product-specific headwinds. Although the company has restored most manufacturing and distribution operations, the combined effect of slowing growth in key franchises and uncertain near-term visibility has driven a sustained de-rating of the stock over the quarter.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots that are currently generating notable performance. Tickeron offers hundreds of automated trading bots that follow thousands of tickers, but only the top-performing and most relevant bots appear in this curated section, making it a useful starting point for traders evaluating AI-driven strategies. The bots vary widely in strategy, timeframe, and performance metrics, from short-term momentum approaches to longer-horizon signals. Exploring the page can help investors identify AI trading tools that align with their own approach and risk tolerance.
BSX Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Boston Scientific's third-quarter results, expected in late October, when management has said it will provide an updated operational and financial outlook incorporating the cyberattack's impact. Key areas of focus include the pace of electrophysiology share stabilization, WATCHMAN referral trends, and any updated full-year 2026 guidance. Competitive developments in the PFA market and the progress of the company's restructuring program will also be important. Regulatory, macroeconomic, and litigation-related developments around prior electrophysiology disclosures remain risks to watch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BSX's RSI Oscillator ascending out of oversold territory
The RSI Indicator for BSX moved out of oversold territory on October 08, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 20 of the 26 cases the stock moved higher. This puts the odds of a move higher at 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 200 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
BSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 51 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 56%.
The Moving Average Convergence Divergence Histogram (MACD) for BSX turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 24 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
BSX moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BSX crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
The Aroon Indicator for BSX entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.564) is normal, around the industry mean (10.930). P/E Ratio (17.858) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices
Industry MedicalNursingServices